Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ayala Pharmaceuticals's quarterly market cap
declined
from Jun. 2023 ($4.78 Mil) to Sep. 2023 ($4.50 Mil) but then
increased
from Sep. 2023 ($4.50 Mil) to Dec. 2023 ($7.91 Mil).
Ayala Pharmaceuticals's annual market cap
declined
from Dec. 2021 ($118.77 Mil) to Dec. 2022 ($5.93 Mil) but then
increased
from Dec. 2022 ($5.93 Mil) to Dec. 2023 ($7.91 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ayala Pharmaceuticals's Enterprise Value for Today is $29.14 Mil.
Ayala Pharmaceuticals (OTCPK:ADXS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ayala Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ayala Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ayala Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Ayala Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ayala Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ayala Pharmaceuticals (ADXS) has a Market Cap of $25.71 Mil as of Sep. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ayala Pharmaceuticals and its competitors.
Is Ayala Pharmaceuticals' Market Cap too high?
Ayala Pharmaceuticals' current Market Cap is $25.71 Mil. The Biotechnology industry median Market Cap is 121.48. Ayala Pharmaceuticals' value of $25.71 Mil is 78.8% below this industry median. Overall, Ayala Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Ayala Pharmaceuticals' Market Cap compare to SCPX and PBM?
Ayala Pharmaceuticals' Market Cap of $25.71 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 121.48. Ayala Pharmaceuticals' value of $25.71 Mil is 78.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.48, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ayala Pharmaceuticals's current Market Cap of $25.71 Mil is 78.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ayala Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 121.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ayala Pharmaceuticals's current Market Cap is $25.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ayala Pharmaceuticals stock overvalued right now?
Ayala Pharmaceuticals (ADXS) has a current Market Cap of $25.71 Mil. The current Market Cap is $25.71 Mil and 78.8% below the Biotechnology industry median of 121.48. Ayala Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ayala Pharmaceuticals (ADXS), the current Market Cap is $25.71 Mil as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.
12GF Score
Get the complete analysis for ADXS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADXS has been successfully added to your 
